Zytax Capsules / Delayed Release
ABBOTT LABORATORIES S.A.
|Pack size||28's (7's Blister x 4)|
|Agent||MODERN PHARMACEUTICAL CO.|
|Retail Price||85.00 AED|
Zytax Capsules / Delayed Release is used for: Major Depressive Disorder (MDD), Fibromyalgia, Diabetic neuropathy, Stress urinary incontinence, Generalized anxiety disorder, Interstitial cystitis, Musculoskeletal pain
Oral Major Depressive Disorder Adult: Initially, 20-30 mg bid or 60 mg once daily, then increase dose in increments of 30 mg/day over 1 wk as tolerated. Max: 120 mg/day. Diabetic Peripheral Neuropathic Pain Adult: 60 mg once daily. Max: 120 mg/day in divided doses. Generalized Anxiety Disorder Adult: 30 or 60 mg once daily. Max: 120 mg/day. Fibromyalgia Adult: Initially, 30 mg once daily for 1 wk, then increase to 60 mg once daily. Elderly Major Depressive Disorder May initiate at 20 mg PO qDay or divided BID; increase to 40-60 mg qDay or divided doses; alternatively, initiate at 30 mg/day for 1 week, then increase to 60 mg/day as tolerated Generalized Anxiety Disorder 30 mg/day PO qDay initially; after 2 weeks, consider increasing to target dose of 60 mg/day Some patients may benefit from doses >60 mg/day; if increased beyond 60 mg/day, use increments of 30 mg/day Maximum dose studied was 120 mg/day; safety of doses >120 mg/day has not been evaluated Hepatic Impairment Avoid use in patients with chronic liver disease or cirrhosis
Generalized Anxiety Disorder <7 years: Safety and efficacy not established 7-17 years: 30 mg PO qDay initially; after 2 weeks, may consider increasing dose to 60 mg/day Recommended dosage range: 30-60 mg/day Some patients may benefit from doses >60 mg/day; if increased beyond 60 mg/day, use increments of 30 mg/day Maximum dose studied was 120 mg/day; safety of doses >120 mg/day has not been evaluated
Renal Impairment Avoid use in patients with severe renal impairment (GFR <30 mL/min)
May be taken with or without food. Swallow whole, do not chew/crush.
Duloxetine is contraindicated in patients with a known hypersensitivity to this drug or any of the inactive ingredients.. Uncontrolled narrow-angle glaucoma. Concomitant use or within 2 wk of MAOIs. Renal and hepatic impairment.
Avoid alcohol and abrupt cessation. May impair ability to drive or engage in task requiring alertness. Increased risk of suicidal thinking and behaviour when used in children and adolescents. Pregnancy, lactation. Lactation: Drug enters breast milk; use not recommended unless benefits greatly outweigh risks
Pregnancy There are no adequate and well-controlled studies administration in pregnant women Use in pregnancy only if the potential benefit justifies the potential risk to the fetus Clinical considerations Neonates exposed during pregnancy to serotonin - norepinephrine reuptake inhibitors (SNRIs) or selective serotonin reuptake inhibitors (SSRIs) have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding which can arise immediately upon delivery Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying These features are consistent with either a direct toxic effect of the SNRIs or SSRIs, or possibly, a drug discontinuation syndrome In some cases, the clinical picture is consistent with serotonin syndrome Data from the published literature report the presence of duloxetine in human milk There are no data on the effect of duloxetine on the breastfed infant or on milk production Women given 40 mg of duloxetine PO BID for 3.5 days; peak concentration measured in breast milk occurred at a median of 3 hrs post-dose Amount of duloxetine in breast milk was ~7 mcg/day while on that dose; estimated daily infant dose was ~2 mcg/kg/day, which is <1% of the maternal dose
Increased risk of serotonin syndrome w/ TCA, SSRI, SNRI, lithium. May increase bleeding risk w/ aspirin, NSAIDs, warfarin and other anticoagulants. Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue. Increased serum levels and risk of toxicity w/ potent CYP1A2 inhibitors (e.g. ciprofloxacin, enoxacin).
Side effects of Duloxetine : >10% Nausea (23-25%), Dry mouth (13-15%), Headache (13-14%), Somnolence (10-12%), Fatigue (10-11%) 1-10% Constipation (10%), Dizziness (10%), Insomnia (10%), Diarrhea (9-10%), Anorexia (8%), Decreased appetite (7-8%), Abdominal pain (6%), Hyperhidrosis (6%), Increased sweating (6%), Agitation (5%), Nasopharyngitis (5%), Vomiting (3-5%), Male sexual dysfunction (2-5%), Abdominal pain (4%), Decreased libido (4%), Musculoskeletal pain (4%), Upper respiratory tract infection (URTI) (4%), Abnormal orgasm (3%), Agitation (3%), Anxiety (3%), Blurred vision (3%), Cough (3%), Influenza (3%), Muscle spasms (3%), Tremor (3%), Abnormal dreams (2%), Dyspepsia (2%), Hot flushes (2%), Nausea (2%), Oropharyngeal pain (2%), Palpitations (2%), Paresthesia (2%), Weight loss (2%), Yawning (2%), Dysuria (>1%), Gastritis (>1%), Rash (>1%)
Mechanism of Action
Duloxetine is a potent inhibitor of neuronal reuptake of serotonin, norepinephrine and to a lesser extent dopamine. It has no significant affinity for adrenergic, muscarinic, cholinergic, histaminergic, opioid, glutamate and GABA receptors. It also does not inhibit monoamine oxidase.
Zytax 30mg Capsules / Delayed Release manufactured by ABBOTT LABORATORIES S.A.. Its generic name is Duloxetine. Zytax is availble in United Arab Emirates. Farmaco UAE drug index information on Zytax Capsules / Delayed Release is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.